Randomization access [Regulatives / Guidelines]

posted by bkrao  – India, 2015-08-10 12:18 (3978 d 00:48 ago) – Posting: # 15209
Views: 5,978

Thanks you.

I required few more suggestions in this regard.

If analyst knows the treatment received by the subject, then the analysis bias is open thing know?

Then the study will be a result oriented, analyst driven study, we can call. but its should not be actual outcome required by the regulatory i hope, kindly suggest.


Thanks you & Regards,
Balaga Koteswara Rao,
Cadila Pharmaceuticals Ltd.

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
254 visitors (0 registered, 254 guests [including 9 identified bots]).
Forum time: 13:07 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5